Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

Table 8 Fully adjusted multivariable logistic regression model of factors associated with SVR12 among 169 patients treated with simeprevir/sofosbuvir ± ribavirin and a confirmed outcome

SMV/SOF ± RBV	Univariable			Multivariable
	OR	95%CI	P value	OR	95%CI	P value
Age, per yr	1.01	0.96-1.06	0.73	0.97	0.87-1.06	0.55
Race, black	0.43	0.15-1.45	0.14	0.66	0.11-4.90	0.66
Gender, female	1.69	0.61-5.44	0.34	0.41	0.08-1.94	0.26
BMI, per kg/m2	0.97	0.87-1.08	0.55	1.02	0.88-1.20	0.75
Diabetes, n (%)	0.64	0.21-2.42	0.47
Naïve to treatment	7.96	1.57-145.37	0.04
PI failure	0.23	0.08-0.61	< 0.01	0.12	0.02-0.52	< 0.01
Ribavirin	0.78	0.29-2.03	0.61	0.64	0.09-3.78	0.63
HCV viral load, per log IU/mL	0.61	0.26-1.26	0.22	0.21	0.05-0.70	0.02
Hemoglobin, g/dL	1.17	0.92-1.48	0.18
Platelet, per 103/μL	1	0.99-1.01	0.19	1.01	0.99-1.02	0.35
ALT, per U/L	1	0.99-1.01	0.37	1.01	0.99-1.02	0.41
AST, per U/L	1	0.99-1.01	0.89
Total Bili, per mg/dL	0.56	0.29-1.06	0.06	0.31	0.08-0.86	0.04
Albumin, per g/dL	1.82	0.72-4.45	0.19
FIB-4 ≥ 3.25	0.66	0.22-1.83	0.44	0.89	0.10-6.29	0.92

BMI: Body mass index; PI: Protease inhibitor; HCV: Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate transaminase; SVM: Simeprevir; SOF: Sofosbuvir; RBV: Ribavirin.